Haleon Announces Director Shareholding Update

Haleon PLC Sponsored ADR ( (HLN) ) has issued an update.

On June 6, 2025, Haleon plc announced a notification and public disclosure regarding transactions by Persons Discharging Managerial Responsibilities, in compliance with the UK Market Abuse Regulation. The Chief Marketing Officer, Tamara Rogers, acquired ordinary shares through dividend reinvestment on June 5, 2025, at the London Stock Exchange. This transaction reflects the company’s ongoing commitment to transparency and regulatory compliance, potentially impacting stakeholder trust and market perception.

The most recent analyst rating on (HLN) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Haleon PLC Sponsored ADR stock, see the HLN Stock Forecast page.

Spark’s Take on HLN Stock

According to Spark, TipRanks’ AI Analyst, HLN is a Outperform.

Haleon’s strong financial performance, characterized by robust cash flow and stable profitability, is a key strength, complemented by positive technical indicators suggesting upward momentum. However, the stock’s valuation appears high, and recent earnings call highlights both opportunities in emerging markets and challenges like FX headwinds and product performance issues. These factors collectively position the stock at a solid yet cautious 73.1 score.

To see Spark’s full report on HLN stock, click here.

More about Haleon PLC Sponsored ADR

Haleon plc is a global leader in consumer health, focusing on delivering better everyday health with humanity. The company’s product portfolio includes Oral Health, Vitamins, Minerals and Supplements, Pain Relief, Respiratory Health, Digestive Health, and Therapeutic Skin Health. Haleon is known for its trusted brands such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu, and Voltaren.

Average Trading Volume: 15,463,367

Technical Sentiment Signal: Buy

Current Market Cap: $48.74B

For an in-depth examination of HLN stock, go to TipRanks’ Stock Analysis page.